The situation following
anti-obesity drug termination is rarely investigated, eventhough a decrease in
body weight needs to be sustained. Therefore, this study examined the impact of twice-daily peripheral administration of 5 mg/kg [N-palm-γGlu-Lys11]
prolactin-releasing peptide 31 (palm11-PrRP31) in mice with diet-induced
obesity (DIO from consuming a high-fat diet) after 28 days of treatment (palm11-PrRP31 group) and after 14 days of
peptide treatment followed by 14 days of discontinuation (palm11-PrRP31 + saline group). At the end of the treatment, cumulative food intake,
body weight and subcutaneous fat
weight/body weight ratio and
leptin plasma level were reduced significantly in both the
palm11-PrRP31 group and the palm11-PrRP31 + saline group compared to the saline control group. This reduction correlated with significantly increased FOSB, a marker of long-term neuronal potentiation, in the nucleus arcuatus and nucleus tractus solitarii, areas known to be affected by the anorexigenic effect of
palm11-PrRP31. Moreover, activation of
leptin-related hypothalamic signaling was registered through an increase in phosphoinositide-3-kinase, increased phosphorylation of
protein kinase B (PKB, AKT) and enhanced
extracellular signal-regulated kinase 1/2 phosphorylation. Besides, lowered apoptotic markers
c-JUN N-terminal kinase and c-JUN phosphorylation were registered in the hypothalami of both palm11-PrRP31-treated groups. This study demonstrates that
palm11-PrRP31 positively affects feeding and
leptin-related hypothalamic signaling, not only after 28 days of treatment but even 14 days after the termination of a 14-day long treatment without the yo-yo effect.